본문바로가기
Q
U
I
C
K

PR

SK bioscience company news updates

Media Zoom

GSK, SK Bioscience Submit BLA for SKYCovione for COVID-19

2022.05.03


 

GSK and SK Bioscience announced the submission of a biologics license application for SKYCovione, a recombinant protein-based COVID-19 vaccine candidate adjuvanted with the GSK’s pandemic adjuvant, to the Korean Ministry of Food and Drug Safety, following positive phase 3 clinical data.

 

The results of the trial showed a superior neutralizing antibody response of the vaccine candidate against SARS-CoV-2 parental strain at 2.93 times than the control vaccine, Vaxzevria (AstraZeneca), an authorized COVID-19 vaccine, 2 weeks after the second dose.